In the adjuvant setting, the addition of trastuzumab to cytotoxic chemotherapy resulted in a remarkable 50% reduction in disease recurrence in a preselected HER2+ breast cancer patient population [109],[110]. The gene discussed is ERBB2; the disease is breast cancer.